OPTN- Liver Registration

Liver Transplant Recipient Registration (TRR) Record
Field Descriptions
The Transplant Recipient Registration (TRR) records are generated and available immediately after a
transplant event is reported through the recipient feedback process in WaitlistSM. A TRR will also be
generated in the case of a living donor transplant, where a recipient was added through the donor
feedback process in Tiedi®. The TRR record is completed by the transplant center performing the
transplant. The registration and hospital discharge follow-up information is combined in this record.
Complete the TRR at hospital discharge or six weeks post transplant, whichever is first. If the
recipient is still hospitalized at six weeks post transplant, provide the most recent information available
regarding the recipient's progress.
The TRR record must be completed within 60 days from the record generation date. See OPTN/UNOS
Policies for additional information. Use the search feature to locate specific policy information on Data
Submission Requirements.
To correct information that is already displayed on an electronic record, call the UNetSM Help Desk at 1800-978-4334.
Recipient Information
Name: Verify the last name, first name and middle initial of the transplant recipient is correct. If the
information is incorrect, corrections may be made on the recipient's TCR record.
DOB: Verify the displayed date is the recipient's date of birth. If the information is incorrect, corrections
may be made on the recipient's TCR record.
SSN: Verify the recipient's social security number is correct. If the information is incorrect, contact the
Help Desk at 1-800-978-4334.
Gender: Verify the recipient's gender is correct. If the information is incorrect, corrections may be made
on the recipient's TCR record.
HIC: Verify the 9 to 11 character Health Insurance Claim number for the recipient indicated on the
recipient's most recently updated TCR record is correct. If the recipient does not have a HIC number,
you may leave this field blank.
Tx Date: Verify the displayed transplant date is the date of the beginning of the first anastomosis. If the
operation started in the evening and the first anastomosis began early the next morning, the transplant
date is the date that the first anastomosis began. The transplant is considered complete when the
cavity is closed and the final skin stitch/staple is applied. The transplant date is indicated immediately
after a transplant event is reported through the recipient feedback process in Waitlist and in the case of
a living donor transplant, where a recipient was added through the donor feedback process in Tiedi.
State of Permanent Residence: Select the name of the state, of the recipient's permanent address, at
the time of transplant. This field is required. (List of State codes)
Permanent Zip: Enter the recipient's zip code, of their permanent address, at the time of transplant.
This field is required.
Provider Information
Recipient Center: The recipient center will display. Verify that the transplant center name, center code,
and the provider number, (6-character Medicare identification number of the hospital where the
transplant recipient was transplanted) are correct.
Surgeon Name: Enter the name of the primary surgeon, who performed the transplant operation, and
under whose name the transplant is billed. This field is required.

NPI #: Enter the 10-character CMS (Center for Medicare and Medicaid Services, formerly HCFA)
assigned National Provider Identifier of the transplant physician. Your hospital billing office may be able
to obtain this number for you. This field is required.
Donor Information
UNOS Donor ID #: The UNOS Donor ID number, reported in the Recipient Feedback, will display.
Each potential donor is assigned an identification number by OPTN/UNOS. This ID number
corresponds to the date the donor information was entered into the OPTN/UNOS computer system.
Donor Type: The donor type, reported in the Recipient Feedback, will display. Verify the recipient's
donor type is correct. If the information is incorrect, contact the Help Desk at 1-800-978-4334.
Deceased indicates the donor was not living at the time of donation.
Living indicates the donor was living at the time of donation.
Patient Status
Primary Diagnosis: Select the primary diagnosis for the disease requiring a transplant for this
recipient. If Other, Specify is selected, enter the primary diagnosis in the space provided. This field is
required. (List of Liver Diagnosis codes)
Date: Last Seen, Retransplanted or Death: Enter the date the hospital reported the recipient as living,
retransplanted (when the data was obtained prior to the recipient's discharge) or the date of the
recipient's death, using the standard 8-digit numeric format of MM/DD/YYYY. This field is required.
Patient Status: Select the appropriate status for this recipient. If Dead is selected, indicate the cause of
death. This field is required. (List of Patient Status codes)
Living
Dead
Retransplanted
Primary Cause of Death: If the Patient Status is Dead, select the patient's cause of death. If
an Other code is selected, enter the other cause of death in the space provided. (List of
Primary Cause of Death codes)
Contributory Cause of Death: If the Patient Status is Dead, select the patient's contributory
cause of death. If an Other code is selected, enter the other cause of death in the space
provided. (List of Contributory Cause of Death codes)
Contributory Cause of Death: If the Patient Status is Dead, select the patient's contributory
cause of death. If an Other code is selected, enter the other cause of death in the space
provided. (List of Contributory Cause of Death codes)
Note: If the patient is being retransplanted, access the patient's last record for their previous
transplant and select Retransplanted in the Patient Status field. This will stop the generation
of TRF records associated with the previous transplant.
Transplant Hospitalization:
Date of Admission to Tx Center: Enter the date the recipient was admitted to the transplant
center, using the 8-digit MM/DD/YYYY format. If the patient was admitted to the hospital before it
was determined a transplant was needed, enter the date it was determined the patient needed a
transplant. This field is required.
Date of Discharge From Tx Center: Enter the date the recipient was released to go home, using
the 8-digit MM/DD/YYYY format. The recipient's hospital stay includes total time spent in different
units of the hospital, including medical and rehab. This information is not required in the TRR
record, but if entered here, it will automatically fill in the future TRF records. It is required in the TRF
record.

Note: Leave this field blank if the recipient was removed from the waiting list with a code of 21,
indicating the recipient died during the transplant procedure.
Was patient hospitalized during the last 90 days prior to the transplant admission: If the
recipient was hospitalized during the last 90 days prior to transplant admission, select Yes. If not,
select No. If unknown, select UNK.
Medical Condition at time of transplant: Select the choice that best describes the recipient's
condition and location just prior to the time of transplant. This field is required. (List of Medical
Condition codes)
In Intensive Care Unit
Hospitalized Not in ICU
Not Hospitalized
Patient on Life Support: If the patient was on life support at the time of transplant, select Yes. If not,
select No. If Yes is selected, check all that apply. If a type of life support used is not listed select Other
Mechanism, Specify and specify the type in the space provided. This field is required.
Ventilator - Select only if the recipient is on continuous invasive ventilation
Artificial Liver
Other Mechanism, Specify
Functional Status: Select the choice that best describes the recipient's functional status just prior to
the time of transplant. This field is required. (List of Functional Status codes)
Note: The Karnofsky Index will display for recipients aged 18 and older.
100% - Normal, no complaints, no evidence of disease
90% - Able to carry on normal activity: minor symptoms of disease
80% - Normal activity with effort: some symptoms of disease
70% - Cares for self: unable to carry on normal activity or active work
60% - Requires occasional assistance but is able to care for needs
50% - Requires considerable assistance and frequent medical care
40% - Disabled: requires special care and assistance
30% - Severely disabled: hospitalization is indicated, death not imminent
20% - Very sick, hospitalization necessary: active treatment necessary
10% - Moribund, fatal processes progressing rapidly
Note: The Lansky Scale will display for recipients aged 1 to 17.
100% - Fully active, normal
90% - Minor restrictions in physically strenuous activity
80% - Active, but tires more quickly
70% - Both greater restriction of and less time spent in play activity
60% - Up and around, but minimal active play; keeps busy with quieter activities
50% - Can dress but lies around much of day; no active play; can take part in quiet
play/activities
40% - Mostly in bed; participates in quiet activities
30% - In bed; needs assistance even for quiet play
20% - Often sleeping; play entirely limited to very passive activities
10% - No play; does not get out of bed
Not Applicable (patient < 1 year old)
Unknown
Note: This evaluation should be in comparison to the person's normal function, indicating how the
patient's disease has affected their normal function.
Physical Capacity: (Complete for recipients older than 18 years of age.) Select the choice that best
describes the recipient's physical capacity just prior to the time of transplant. If the recipient's Medical
Condition indicates they are hospitalized, select Not Applicable (hospitalized). (This field is optional
for adult recipients only.) (List of Physical Capacity codes)

No Limitations
Limited Mobility
Wheelchair bound or more limited
Not Applicable (hospitalized)
Unknown
Physical Capacity is the ability to perform bodily activities such as walking, dressing, bathing,
grooming, etc.
Cognitive Development: (Complete for recipients 18 years of age or younger.) Select the choice that
best describes the recipient's cognitive development just prior to the time of transplant. This field is
required.
Definite Cognitive Delay/Impairment (verified by IQ score <70 or unambiguous behavioral
observation)
Probable Cognitive Delay/Impairment (not verified or unambiguous but more likely than not,
based on behavioral observation or other evidence)
Questionable Cognitive Delay/Impairment (not judged to be more likely than not, but with some
indication of cognitive delay/impairment such as expressive/receptive language and/or learning
difficulties)
No Cognitive Delay/Impairment (no obvious indicators of cognitive delay/impairment)
Not Assessed
Motor Development: (Complete for recipients 18 years of age or younger.) Select the choice that best
describes the recipient's motor development just prior to the time of transplant. This field is required.
(List of Motor Development codes)
Definite Motor Delay/Impairment (verified by physical exam or unambiguous behavioral
observation)
Probable Motor Delay/Impairment (not verified or unambiguous but more likely than not, based
on behavioral observation or other evidence)
Questionable Motor Delay/Impairment (not judged to be more likely than not, but with some
indication of motor delay/impairment)
No Motor Delay/Impairment (no obvious indicators of motor delay/impairment)
Not Assessed
Working for income: (Complete for recipients 19 years of age or older.) If the recipient was working for
income just prior to the time of transplant, select Yes. If not, select No. If reporting the recipient's death,
indicate if the recipient was working for income just prior to death. This field is required.
If Yes: If Yes is selected, indicate the candidate's working status just prior to the time of transplant.
(This field is optional for adult candidates only.) (List of Working codes)
Working Full Time
Working Part Time due to Demands of Treatment
Working Part Time due to Disability
Working Part Time due to Insurance Conflict
Working Part Time due to Inability to Find Full Time Work
Working Part Time due to Patient Choice
Working Part Time Reason Unknown
Working, Part Time vs. Full Time Unknown
If No, Not Working Due To: If No is selected, indicate the reason why the candidate is not
working just prior to the time of transplant. (This field is optional for adult candidates only.) (List of
Not Work Reason codes)

Disability - A physical or mental impairment that interferes with or prevents a candidate from
working (e.g. arthritis, mental retardation, cerebral palsy, etc).
Demands of Treatment - An urgent medical treatment that prevents a candidate from working
(e.g. dialysis).
Insurance Conflict - Any differences between a candidate and insurance company that
prevents them from working.
Inability to Find Work - The lack of one's ability to find work (e.g. lack of transportation, work
experience, over qualification, unavailable work, etc.).
Patient Choice - Homemaker - A candidate who chooses to manage their own household,
instead of performing work for pay.
Patient Choice - Student Full Time/Part Time - A candidate who is enrolled and/or
participating in college.
Patient Choice - Retired - A candidate who no longer has an active working life such as an
occupation, business or office job.
Patient Choice - Other - Any reason not listed above that would prevent a candidate from
working.
Not Applicable - Hospitalized - Select only if the patient's Medical Condition indicates they
are in the hospital.
Unknown
Academic Progress: (Complete for recipients less than 19 years of age.) Select the choice that best
describes the recipient's academic progress just prior to the time of transplant. If the candidate is less
than 5 years old or has graduated from high school, select Not Applicable < 5 years old/High School
graduate or GED. This field is required. (List of Academic Progress codes)
Within One Grade Level of Peers
Delayed Grade Level
Special Education
Not Applicable < 5 years old/High School graduate or GED
Status Unknown
Academic Activity Level: (Complete for recipients less than 19 years of age.) Select the choice that
best describes the recipient's academic activity level just prior to the time of transplant. If the recipient is
less than 5 years old or has graduated from high school, select Not Applicable < 5 years old/High
School graduate or GED. This field is required. (List of Academic Activity Level codes)
Full academic load
Reduced academic load
Unable to participate in academics due to disease or condition
Unable to participate regularly in academics due to dialysis
Not Applicable < 5 years old/High School graduate or GED
Status Unknown
Source of Payment:
Primary: Select as appropriate to indicate the recipient's source of primary payment (largest
contributor) for the transplant. This field is required. (List of Primary Insurance codes)
Private insurance refers to funds from agencies such as Blue Cross/Blue Shield, etc. It also
refers to any worker's compensation that is covered by a private insurer.
Public insurance - Medicaid refers to state Medicaid funds.

Public insurance - Medicare FFS (Fee-for-Service) refers to funds from the government in
which doctors and other health care providers are paid for each service provided to a recipient.
For additional information about Medicare, see
http://www.medicare.gov/Choices/Overview.asp.
Public insurance - Medicare & Choice (also known as Medicare Managed Care) refers to
funds from the government in which doctors and other health care providers are paid for each
service provided to a recipient, along with additional benefits such as coordination of care or
reducing-out-of-pocket expenses. Sometimes a recipient may receive additional benefits such
as prescription drugs. For additional information about Medicare, see
http://www.medicare.gov/Choices/Overview.asp.
Public insurance - CHIP (Children's Health Insurance Program)
Public insurance - Department of VA refers to funds from the Veterans Administration.
Public insurance - Other government
Self indicates that the recipient will pay for the cost of transplant.
Donation indicates that a company, institution, or individual(s) donated funds to pay for the
transplant and care of the recipient.
Free Care indicates that the transplant hospital will not charge recipient for the costs of the
transplant operation.
Foreign Government, Specify refers to funds provided by a foreign government (Primary
only) Specify foreign country in the space provided. (List of Foreign Country codes)
Secondary: Select check as appropriate to indicate the recipient's source of secondary payment.
(This field is optional.) (List of Secondary Insurance codes)
Private insurance refers to funds from agencies such as Blue Cross/Blue Shield, etc. It also
refers to any worker's compensation that is covered by a private insurer.
Public insurance - Medicaid refers to state Medicaid funds.
Public insurance - Medicare FFS (Fee-for-Service) refers to funds from the government in
which doctors and other health care providers are paid for each service provided to a recipient.
For additional information about Medicare, see
http://www.medicare.gov/Choices/Overview.asp.
Public insurance - Medicare & Choice (also known as Medicare Managed Care) refers to
funds from the government in which doctors and other health care providers are paid for each
service provided to a recipient, along with additional benefits such as coordination of care or
reducing-out-of-pocket expenses. Sometimes a recipient may receive additional benefits such
as prescription drugs). For additional information about Medicare, see
http://www.medicare.gov/Choices/Overview.asp.
Public insurance - CHIP (Children's Health Insurance Program)
Public insurance - Other government
Self indicates that the recipient will pay for the cost of transplant.
Donation indicates that a company, institution, or individual(s) donated funds to pay for the
transplant and care of the recipient.
Free Care indicates that the transplant hospital will not charge the recipient for the costs of the
transplant operation.
None - Select if the recipient does not have a secondary source of payment.
Clinical Information: PRETRANSPLANT

Date of Measurement: (Complete for recipients 18 years of age or younger.) Enter the date, using the
8-digit format of MM/DD/YYYY, the recipient’s height and weight were measured.
Height: Enter the height of the recipient, just prior to the time of transplant, in feet and inches or
centimeters. If the recipient’s height is unavailable, select the appropriate status from the ST field
(Missing, Unknown, N/A, Not Done). (List of Status codes) For recipients 18 years old or younger at
the time of transplant, UNet will generate and display calculated percentiles based on the 2000 CDC
growth charts. This field is required.
Weight: Enter the weight of the recipient, just prior to the time of transplant, in pounds or kilograms. If
the recipient’s weight is unavailable, select the appropriate status from the ST field (Missing,
Unknown, N/A, Not Done). (List of Status codes) For recipients 18 years old or younger at the time of
transplant, UNet will generate and display calculated percentiles based on the 2000 CDC growth
charts. This field is required.
BMI (Body Mass Index): The recipient's BMI will display. For candidates less than 20 years of age at
the time of transplant, UNet will generate and display calculated percentiles based on the 2000 CDC
growth charts.
Percentiles are the most commonly used clinical indicator to assess the size and growth patterns
of individual children in the United States. Percentiles rank the position of an individual by indicating
what percent of the reference population the individual would equal or exceed (i.e. on the weightfor-age growth charts, a 5 year-old girl whose weight is at the 25th percentile, weighs the same or
more than 25 percent of the reference population of 5-year-old girls, and weighs less than 75
percent of the 5-year-old girls in the reference population). For additional information about CDC
growth charts, see http://www.cdc.gov/.
Note: Users who check the BMI percentiles against the CDC calculator may notice a discrepancy
that is caused by the CDC calculator using 1 decimal place for height and weight and UNetsm using
4 decimal places for weight and 2 for height.
Previous Transplants: The three most recent transplant(s), indicated on the recipient's validated
Transplant Recipient Registration (TRR) record(s), will display. Verify all previous transplants listed by
organ type, transplant date and graft failure date.
Note: The three most recent transplants on record for this recipient will be displayed for verification. If
there are any prior transplants that are not listed here, contact the UNet Help Desk at 1-800-9784334 or [email protected] to determine if the transplant event is in the database.
Viral Detection:
HIV Serostatus: Select the serology results from the drop-down list. This field is required.
Positive
Negative
Not Done
UNK/Cannot Disclose
Definition: Human Immunodeficiency Virus - Any of several retroviruses and especially HIV-1
that infect and destroy helper T cells of the immune system causing the marked reduction in
their numbers that is diagnostic of AIDS.
CMV IgG: Select the serology results from the drop-down list. This field is required.
Positive
Negative
Not Done
UNK/Cannot Disclose
Definition: Cytomegalovirus - A herpesvirus (genus Cytomegalovirus) that causes cellular
enlargement and formation of eosinophilic inclusion bodies especially in the nucleus and that
acts as an opportunistic infectious agent in immunosuppressed conditions (as AIDS).

CMV IgM: Select the serology results from the drop-down list. This field is required.
Positive
Negative
Not Done
UNK/Cannot Disclose
Definition: Cytomegalovirus - A herpesvirus (genus Cytomegalovirus) that causes cellular
enlargement and formation of eosinophilic inclusion bodies especially in the nucleus and that
acts as an opportunistic infectious agent in immunosuppressed conditions (as AIDS).
HBV Core Antibody: Select the serology results from the drop-down list. This field is required.
Positive
Negative
Not Done
UNK/Cannot Disclose
Definition: Hepatitis B Virus - A sometimes fatal hepatitis caused by a double-stranded DNA
virus (genus Orthohepadnavirus of the family Hepadnaviridae) that tends to persist in the blood
serum and is transmitted especially by contact with infected blood (as by transfusion or by
sharing contaminated needles in illicit intravenous drug use) or by contact with other infected
bodily fluids (as during sexual intercourse) -- also called serum hepatitis.
HBV Surface Antigen: Select the serology results from the drop-down list. This field is required.
Positive
Negative
Not Done
UNK/Cannot Disclose
Definition: Hepatitis B Virus - A sometimes fatal hepatitis caused by a double-stranded DNA
virus (genus Orthohepadnavirus of the family Hepadnaviridae) that tends to persist in the blood
serum and is transmitted especially by contact with infected blood (as by transfusion or by
sharing contaminated needles in illicit intravenous drug use) or by contact with other infected
bodily fluids (as during sexual intercourse) -- also called serum hepatitis.
HCV Serostatus: Select the serology results from the drop-down list. This field is required.
Positive
Negative
Not Done
UNK/Cannot Disclose
Definition: Hepatitis C Virus - A disease caused by a flavivirus that is usually transmitted by
parenteral means (as injection of an illicit drug, blood transfusion, or exposure to blood or blood
products) and that accounts for most cases of non-A, non-B hepatitis.
EBV Serostatus: Select the serology results from the drop-down list. This field is required.
Positive
Negative
Not Done
UNK/Cannot Disclose
Definition: (Epstein-Barr Virus) - A herpesvirus (genus Lymphocryptovirus) that causes
infectious mononucleosis and is associated with Burkitt's lymphoma and nasopharyngeal
carcinoma -- abbreviation EBV; called also EB virus.
Any tolerance induction technique used: If the recipient used any tolerance induction technique,
select Yes. If not, select No. If unknown, select UNK.
Tolerance Induction: Before a transplant occurs, the immune system can be prepared for the
upcoming graft by attempting to induce graft tolerance. This can be achieved through a variety of

protocols. The following are examples of tolerance induction protocols from the Primer on
Transplantation 1-4)*:
Administration of moAbs (monoclonal antibodies) targeting cell surface molecules such as CD4,
CD8, CD25, LFA-1, or the TCR (T-cell receptor)
Blockade of the costimulation pathways of T cell activation
Institution of pharmacological drug including steroids, rapamycin, cyclosporine
Donor specific transfusion
Combinations of immunosuppressive drugs and plasmaphoresis to decrease the recipient PRA
in living donor transplants (member example)
* Norman, Douglas J., Turka, Laurence A. Primer on Transplantation, Second Edition page
40, American Society of Transplantation 2001
Pretransplant Lab Date: Enter the pre-transplant lab date, using the 8-digit MM/DD/YYYY format.
(This field is optional.)
SGPT/ALT: (Serum Glutamic Pyruvic Transaminase/Alanine Aminotransferase): Enter the lab
value for this enzyme in U/L. If values are unavailable, select the appropriate status from the ST
field (Missing, Unknown, N/A, Not Done). (List of Status codes)
Malignancies between listing and transplant: If the recipient has a history of any malignancies
between listing and transplant, select Yes. If the recipient has not had a history of any malignancies
between listing and transplant, select No. If unknown, select UNK. If Yes is selected, select the type(s)
of malignancy. If Other, specify is selected, indicate the type of tumor in the space provided. This field
is required. (List of Adult Malignancy codes) (List of Pediatric Malignancy codes)
Skin Melanoma
Skin Non-Melanoma
CNS Tumor
Genitourinary
Breast
Thyroid
Tongue/Throat/Larynx
Lung
Leukemia/Lymphoma
Liver
Hepatoblastoma (This selection is available to pediatric recipients only.)
Hepatocellular Carcinoma
Other, specify
Note: This question is NOT applicable for patients receiving living donor transplants who were
never on the waiting list.
Clinical Information: Transplant Procedure
Multiple Organ Recipient: Other organs, that were reported as being transplanted in the Recipient
Feedback, will display. Verify the other organs transplanted at this time are correct. If incorrect, contact
the Help Desk.
Were extra vessels used in the transplant procedure: If extra vessels (vascular allografts) were
used in the transplant procedure, as indicated on the Waitlist Removal, YES displays.
Vessel Donor ID: The Donor ID entered on the Waitlist Removal displays.
Note: Donor IDs entered for this question must be from deceased donors. All deceased donor
extra vessels must be
monitored due to the potential for disease transmission.

Note: If the extra vessels used in a transplant procedure are procured from a tissue processing
organization, they are not reported in UNet.
Surgical Procedure: Select type procedure type. This field is optional. (List of Surgical Procedure
codes)
Orthotopic - graft replaced native liver
Heterotopic - graft was transplanted alongside native liver
Procedure Type: Verify the procedure type is correct. (List of Procedure Type codes)
Whole Liver
Partial Liver, remainder not Tx or Living Transplant
Split Liver
Whole Liver with Pancreas (Technical Reasons)
Partial Liver with Pancreas (Technical Reasons)
Split Liver with Pancreas (Technical Reasons)
Split Type: If the Procedure Type is a Partial or Split type, select the specific type. This field is
required.
Partial (List of Partial Type codes)
Right Lobe Without Middle Hepatic Vein (segments 5,6,7,8)
Right Lobe with Middle Hepatic Vein (segments 4,5,6,7,8)
Left Lobe (segments 2,3,4)
Left Lateral (segments 2,3)
Split (List of Split Type codes)
Left Lobe In Situ (segments 2,3,4)
Left Lobe on the Bench (segments 2,3,4)
Left Lobe with Caudate In Situ (segments 1,2,3,4)
Left Lobe with Caudate on the Bench (segments 1,2,3,4)
Left Lateral Segment In Situ (segments 2,3)
Left Lateral Segment on the Bench (segments 2,3)
Right Lobe Without Middle Hepatic Vein In Situ (segments 5,6,7,8)
Right Lobe Without Middle Hepatic Vein on the Bench (segments 5,6,7,8)
Right Lobe with Middle Hepatic Vein In Situ (segments 4,5,6,7,8)
Right Lobe with Middle Hepatic Vein on the Bench (segments 4,5,6,7,8)
Preservation Information:
Warm Ischemia Time (Include anastomotic time): Is the number of minutes between the time of
removal from cold storage and the time of reperfusion with warm blood, whether venous or arterial,
and is usually between 20 minutes and 4 hours. (This field is optional for adult recipients only.) If
the time is unavailable, select the appropriate status from the ST field (Missing, Unknown,
N/A, Not Done). (List of Status codes)
Total Cold Ischemia Time (If pumped, include pump time): The number of hours between the
time of preservation of the organ and the time of removal from cold storage. If the time is
unavailable, select the appropriate status from the ST field (Missing, Unknown, N/A, Not Done).
This field is required. (List of Status codes)
Note: Enter the time in hours and decimal parts of an hour. For example, 1 hour should be entered
as "1", "1.0" or "1.00"; 1 hour and 30 minutes should be entered as "1.5" or "1.50" not "1.30".
To report the minutes, divide the number of minutes into 60 and record 2 decimal places.
Example: 7hrs 19 minutes = 7.32 ( 60 divided by 19 =.32)
Note: Select N/A from the ST field for Preservation Information if the recipient was removed from
the waiting list with a code 21, indicating the recipient died during the transplant procedure.

Risk Factors: For each of the risk factors listed, indicate the recipient's history of the risk factor at the
time of this transplant.
Did Patient receive 5 or more units of packed red blood cells within 48 hours prior to
transplantation due to spontaneous portal hypertensive bleeding: If the recipient received 5 or
more units of packed red blood cells within 48 hours prior to transplantation due to spontaneous
portal hypertensive bleeding, select Yes. If not, select No. If unknown, select UNK.
Spontaneous Bacterial Peritonitis: If the recipient was experiencing bacterial peritonitis, select
Yes. If not, select No. If unknown, select UNK.
Previous Abdominal Surgery: If the recipient had any abdominal surgery prior to this transplant,
select Yes. If not, select No. If unknown, select UNK. This field is required.
Portal Vein Thrombosis: If the recipient has experienced portal vein thrombosis prior to this
transplant, select Yes. If not, select No. If unknown, select UNK. This field is required.
Transjugular Intrahepatic Portacava Stint Shunt: If the recipient has required TIPSS prior to this
transplant, select Yes. If not, select No. If unknown, select UNK. This field is required.
Incidental Tumor found at time of Transplant: If an incidental tumor was found at the time of
transplant in an organ that was removed from the recipient, select Yes. If not, select No. If unknown,
select UNK. If Yes is selected, specify the tumor type. If Other Primary Liver Tumor, Specify is
selected, enter the name in the space provided. (List of Liver Tumor codes)
Hepatocellular Adenoma
Hemangioma
Hemangioendothelioma
Angiomyolipoma
Bile Duct Cystadenocarcinoma
Cholangiocarcinoma
Hepatocellular Carcinoma
Hepatoblastoma
Angiosarcoma
Other Primary Liver Tumor, Specify
Clinical Information: Post Transplant
Pathology Conf. Liver Diag. of Hospital Discharge: Select the most definitive primary liver diagnosis,
based on clinical and pathological evidence on the native/replaced liver. Be specific. If the diagnosis is
cirrhosis or hepatitis, choose the diagnosis that indicates the correct etiology and if the hepatitis is
chronic or acute. If an Other code is selected, enter the specific diagnosis in the space provided. This is
to confirm the reason for transplant. This information will display as read-only on TRF records. This
field is required (List of Pathology-Confirmed Diagnosis codes)
Note: Enter the same information that was entered for the Primary Diagnosis at the time of
hospital discharge if the recipient was removed from the waiting list with a code 21, indicating
the recipient died during the transplant procedure.
Graft Status: If the liver graft is functioning, select Functioning. If the graft is not functioning at the
time of hospital discharge or time of report, select Failed. If failed, complete the remainder of this
section. This field is required.
Note: Select Functioning if the recipient was removed from the waiting list with a code 21,
indicating the recipient died during the transplant procedure.
Note: If death is indicated for the recipient, and the death was a result of some other factor
unrelated to graft failure, select Functioning.
If Failed, provide the following information:

Date of Failure: Enter the date of graft failure using the standard 8-digit numeric format of
MM/DD/YYYY.
Causes of Graft Failure: For each cause of graft failure listed, select Yes, No, or UNK. If
Other Specify is selected, enter the cause of graft failure in the space provided.
Primary Graft Failure
Vascular Thrombosis
Biliary Tract Complication
Hepatitis: DeNovo
Hepatitis: Recurrent
Recurrent Disease (non-Hepatitis)
Acute Rejection
Infection
Other, Specify
If Vascular Thrombosis is selected for pediatric recipients, complete the following
information:
Hepatic arterial thrombosis: If the recipient had a hepatic arterial thrombosis, select
Yes. If not, select No. If unknown, select Unknown.
Hepatic outflow obstruction: If the recipient had hepatic outflow obstruction, select
Yes. If not, select No. If unknown, select Unknown.
Portal vein thrombosis: If the recipient had portal vein thrombosis, select Yes. If not,
select No. If unknown, select Unknown.
Discharge Lab Date:
Enter the values, at discharge, for the Serum Lab Data listed below. If any of the data values are
unavailable, select the appropriate status from the ST field (Missing, Unknown, N/A, Not Done).
(List of Status codes)
Discharge Lab Date: Enter the discharge lab date in the space provided, using the 8-digit
MM/DD/YYYY format.
Total Bilirubin: Enter the lab value for total serum bilirubin in mg/dl.
SGPT/ALT: Enter the lab value for Serum Glutamic Pyruvic Transaminase/Alanine
Aminotransferas in U/L taken closest to discharge.
Serum Albumin: Enter the lab value for the serum albumin value, in g/dl, taken closest to the time
of transplant.
Serum Creatinine: Enter the lab value for the serum creatinine value in mg/dl.)
INR: International Normalized Ratio. Enter the ratio of the prothrombin time (in seconds) to the
control prothrombin time (in seconds) if Prothrombin Time and Control have not been entered
above. Otherwise, leave this field blank.
Note: Select N/A from the ST field for all questions listed above if the recipient was removed from
the waiting list with a code 21, indicating the recipient died during the transplant procedure.
Did patient have any acute rejection episodes between transplant and discharge: If the recipient
had any acute rejection episodes between transplant and discharge, select a Yes choice. If not, select
No. If a Yes choice is selected, then indicate if a biopsy was done to confirm acute rejection. This field
is required. (List of Any Acute Rejection Episodes codes)
Yes, at least one episode treated with anti-rejection agent
Yes, none treated with additional anti-rejection agent
No

Was Biopsy done to confirm acute rejection: If the recipient had an acute kidney rejection
episode, indicate whether biopsy confirmed acute rejection by selecting Yes. If a biopsy was not
done, select Biopsy not done. If unknown, select Unknown. (List of Biopsy Confirmed codes)
Biopsy not done
Yes, rejection confirmed
Yes, rejection not confirmed
Treatment
Biological or Anti-viral Therapy: If biological or anti-viral therapy is being administered to the
recipient, select Yes. If not, select No. If unknown or can't disclose, select Unknown/Cannot Disclose.
If Yes is selected, check all that apply. If a therapy, other than those listed, was administered, select
Other, Specify and enter the therapy in the space provided. (List of Anti-viral Treatment codes)
Acyclovir (Zovirax)
Cytogam (CMV)
Gamimune
Gammagard
Ganciclovir (Cytovene)
Valgancyclovir (Valcyte)
HBIG (Hepatitis B Immune Globulin)
Flu Vaccine (Influenza Virus)
Lamivudine (Epivir) (for treatment of Hepatitis B)
Other, Specify
Valacyclovir (Valtrex)
Other Therapies: If the recipient received other therapies, select Yes. If not, select No. If Yes is
selected, check all that apply. (List of Other Therapies codes)
Photopheresis
Plasmapheresis
Total Lymphoid Irradiation (TLI)
Note: If the recipient was removed from the waiting list with a code 21, indicating the recipient died
during the transplant procedure, select No for all Biologicals or Anti-viral.
Immunosuppressive Information
Are any medications given currently for maintenance or anti-rejection: If medications have been
given to the recipient for maintenance or anti-rejection during the time between transplant and hospital
discharge, or 6 weeks post-transplant if the recipient has not been discharged, select Yes. If not, select
No. If Yes, complete the sections below. This field is required.
Did the recipient participate in any clinical research protocol for immunosuppressive
medications: If the recipient participated in clinical research for immunosuppressive medications,
select Yes. If not, select No. If Yes, specify in the space provided.
Immunosuppressive Medications
For each of the immunosuppressive medications listed, select Ind.(Induction), Maint (Maintenance) or
AR (Anti-rejection) to indicate all medications that were prescribed for the recipient during the initial
transplant hospitalization period, and for what reason. If a medication was not given, leave the
associated box blank.
Induction (Ind.) immunosuppression includes all medications given for a short finite period in the
perioperative period for the purpose of preventing acute rejection. Though the drugs may be
continued after discharge for the first 30 days after transplant, it will not be used long-term for
immunosuppressive maintenance. Induction agents are usually polyclonal, monoclonal, or IL-2

receptor antibodies (e.g., Methylprednisolone, Atgam, Thymoglobulin, OKT3, Simulect, or
Zenapax). Some of these drugs might be used for another finite period for rejection therapy and
would be recorded as rejection therapy if used for this reason. For each induction medication
indicated, enter the total number of days the drug was actually administered in the space provided.
For example, if Simulect or Zenapax was given in 2 doses a week apart then the total number of
days would be 2, even if the second dose was given after the patient was discharged.
Maintenance (Maint) includes all immunosuppressive medications given before, during or after
transplant for varying periods of time which may be either long-term or intermediate term with a
tapering of the dosage until the drug is either eliminated or replaced by another long-term
maintenance drug (e.g., Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil,
Azathioprine, or Rapamycin). This does not include any immunosuppressive medications given to
treat rejection episodes, or for induction.
Anti-rejection (AR) immunosuppression includes all immunosuppressive medications given for the
purpose of treating an acute rejection episode during the initial post-transplant period or during a
specific follow-up period, usually up to 30 days after the diagnosis of acute rejection (e.g.,
Methylprednisolone, Atgam, OKT3, or Thymoglobulin). When switching maintenance drugs (e.g.,
from Tacrolimus to Cyclosporine; or from Mycophenolate Mofetil to Azathioprine) because of
rejection, the drugs should not be listed under AR immunosuppression, but should be listed under
maintenance immunosuppression.
Note: As further clarification, drugs that are used with the intention to maintain recipients longterm are medications such as Tacrolimus, Cyclosporine, Azathioprine, Mycophenolate
Mofetil and Prednisone. These maintenance medications should not be listed as AR
medications to treat acute rejection. When patients have a true acute rejection, they are
given anti-rejection medication such as steroids, OKT3, ATG, Simulect and Zenapax, in
addition to the maintenance medications. These are the medications that should be
selected as anti-rejection.
If an immunosuppressive medication other than those listed is being administered (e.g., new
monoclonal antibodies), select Ind., Maint, or AR next to Other Immunosuppressive Medication
field, and enter the full name of the medication in the space provided. Do not list nonimmunosuppressive medications.
If the number of days is unavailable, select the appropriate status from the applicable Status field
(Missing, Unknown, N/A, Not Done).(List of Status codes)
Other Immunosuppressive Medications
For each of the immunosuppressive medications listed, select Ind.(Induction), Maint (Maintenance) or
AR (Anti-rejection) to indicate all medications that were prescribed for the recipient during the initial
transplant hospitalization period, and for what reason. If a medication was not given, leave the
associated box blank.
Induction (Ind.) immunosuppression includes all medications given for a short finite period in the
perioperative period for the purpose of preventing acute rejection. Though the drugs may be
continued after discharge for the first 30 days after transplant, it will not be used long-term for
immunosuppressive maintenance. Induction agents are usually polyclonal, monoclonal, or IL-2
receptor antibodies (e.g., Methylprednisolone, Atgam, Thymoglobulin, OKT3, Simulect, or
Zenapax). Some of these drugs might be used for another finite period for rejection therapy and
would be recorded as rejection therapy if used for this reason. For each induction medication
indicated, enter the total number of days the drug was actually administered in the space provided.
For example, if Simulect or Zenapax was given in 2 doses a week apart then the total number of
days would be 2, even if the second dose was given after the patient was discharged.
Maintenance (Maint) includes all immunosuppressive medications given before, during or after
transplant for varying periods of time which may be either long-term or intermediate term with a
tapering of the dosage until the drug is either eliminated or replaced by another long-term

maintenance drug (e.g., Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil,
Azathioprine, or Rapamycin). This does not include any immunosuppressive medications given to
treat rejection episodes, or for induction.
Anti-rejection (AR) immunosuppression includes all immunosuppressive medications given for the
purpose of treating an acute rejection episode during the initial post-transplant period or during a
specific follow-up period, usually up to 30 days after the diagnosis of acute rejection (e.g.,
Methylprednisolone, Atgam, OKT3, or Thymoglobulin). When switching maintenance drugs (e.g.,
from Tacrolimus to Cyclosporine; or from Mycophenolate Mofetil to Azathioprine) because of
rejection, the drugs should not be listed under AR immunosuppression, but should be listed under
maintenance immunosuppression.
Note: As further clarification, drugs that are used with the intention to maintain recipients longterm are medications such as Tacrolimus, Cyclosporine, Azathioprine, Mycophenolate
Mofetil and Prednisone. These maintenance medications should not be listed as AR
medications to treat acute rejection. When patients have a true acute rejection, they are
given anti-rejection medication such as steroids, OKT3, ATG, Simulect and Zenapax, in
addition to the maintenance medications. These are the medications that should be
selected as anti-rejection.
If an immunosuppressive medication other than those listed is being administered (e.g., new
monoclonal antibodies), select Ind., Maint, or AR next to Other Immunosuppressive Medication
field, and enter the full name of the medication in the space provided. Do not list nonimmunosuppressive medications.
If the number of days is unavailable, select the appropriate status from the applicable Status field
(Missing, Unknown, N/A, Not Done).(List of Status codes)
Investigational Immunosuppressive Medications
For each of the immunosuppressive medications listed, select Ind.(Induction), Maint (Maintenance) or
AR (Anti-rejection) to indicate all medications that were prescribed for the recipient during the initial
transplant hospitalization period, and for what reason. If a medication was not given, leave the
associated box blank.
Induction (Ind.) immunosuppression includes all medications given for a short finite period in the
perioperative period for the purpose of preventing acute rejection. Though the drugs may be
continued after discharge for the first 30 days after transplant, it will not be used long-term for
immunosuppressive maintenance. Induction agents are usually polyclonal, monoclonal, or IL-2
receptor antibodies (example: Methylprednisolone, Atgam, Thymoglobulin, OKT3, Simulect, or
Zenapax). Some of these drugs might be used for another finite period for rejection therapy and
would be recorded as rejection therapy if used for this reason. For each induction medication
indicated, enter the total number of days the drug was actually administered in the space provided.
For example, if Simulect or Zenapax was given in 2 doses a week apart then the total number of
days would be 2, even if the second dose was given after the patient was discharged.
Maintenance (Maint) includes all immunosuppressive medications given before, during or after
transplant for varying periods of time which may be either long-term or intermediate term with a
tapering of the dosage until the drug is either eliminated or replaced by another long-term
maintenance drug (e.g., Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil,
Azathioprine, or Rapamycin). This does not include any immunosuppressive medications given to
treat rejection episodes, or for induction.
Anti-rejection (AR) immunosuppression includes all immunosuppressive medications given for the
purpose of treating an acute rejection episode during the initial post-transplant period or during a
specific follow-up period, usually up to 30 days after the diagnosis of acute rejection (example:
Methylprednisolone, Atgam, OKT3, or Thymoglobulin). When switching maintenance drugs
(example: from Tacrolimus to Cyclosporine; or from Mycophenolate Mofetil to Azathioprine)

because of rejection, the drugs should not be listed under AR immunosuppression, but should be
listed under maintenance immunosuppression.
Note: As further clarification, drugs that are used with the intention to maintain recipients longterm are medications such as Tacrolimus, Cyclosporine, Azathioprine, Mycophenolate
Mofetil and Prednisone. These maintenance medications should not be listed as AR
medications to treat acute rejection. When patients have a true acute rejection, they are
given anti-rejection medication such as steroids, OKT3, ATG, Simulect and Zenapax, in
addition to the maintenance medications. These are the medications that should be
selected as anti-rejection.
If an immunosuppressive medication other than those listed is being administered (e.g., new
monoclonal antibodies), select Ind., Maint, or AR next to Other Immunosuppressive Medication
field, and enter the full name of the medication in the space provided. Do not list nonimmunosuppressive medications.
If the number of days is unavailable, select the appropriate status from the applicable Status field
(Missing, Unknown, N/A, Not Done).(List of Status codes)
Drug Codes (List of Drug Codes)
Immunosuppressive Medications
Steroids (Prednisone,Methylprednisolone,Solumedrol,Medrol,Decadron)
Atgam (ATG)
OKT3 (Orthoclone, Muromonab)
Thymoglobulin
Simulect - Basiliximab
Zenapax - Daclizumab
Azathioprine (AZA, Imuran)
EON (Generic Cyclosporine)
Gengraf (Abbott Cyclosporine)
Other generic Cyclosporine, specify brand:
Neoral (CyA-NOF)
Sandimmune (Cyclosporine A)
CellCept (Mycophenolate Mofetil; MMF)
Generic MMF (Generic CellCept)
Prograf (Tacrolimus, FK506)
Generic Tacrolimus (Generic Prograf)
Modified Release Tacrolimus FK506E (MR4)
Sirolimus (RAPA, Rapamycin, Rapamune)
Myfortic (Mycophenolate Sodium)
Other Immunosuppressive Medications
Campath - Alemtuzumab (anti-CD52)
Cyclophosphamide (Cytoxan)
Leflunomide (LFL, Arava)
Methotrexate (Folex, PFS, Mexate-AQ, Rheumatrex)

Other Immunosuppressive Medication, Specify
Rituximab
Investigational Immunosuppressive Medications
Everolimus (RAD, Certican)
Other Immunosuppressive Medication, Specify